The Top 5 Biosimilar Articles for the Week of December 17

December 21, 2018

The Center for Biosimilars® recaps the top news for the week of December 17, 2018.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of December 17.

Number 5: A real-world study has underscored the safety and effectiveness of Celltrion’s infliximab biosimilar, CT-P13, in patients with Crohn disease.

Number 4: A district court in Pennsylvania recently denied Johnson and Johnsons motion to dismiss the antitrust claim brought against the company by Walgreen and Kroger in regard to sales of J&J’s reference infliximab product, Remicade.

Number 3: Last week, insurer Cigna and pharmacy benefit manager Express Scripts overcame 2 hurdles to completing their 67-billion-dollar merger as New York and California insurance regulators signed off on the deal.

Number 2: Pfizer recently announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion of its proposed bevacizumab biosimilar.

Number 1: The FDA approved Celltrion and Teva’s biosimilar trastuzumab, Herzuma, for the treatment of HER2-positive breast cancer.

Finally, last week, our e-newsletter asked if the United States should rein in the number of patents it grants to drugs.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.